Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir

Lawrence Corey, Adrian Mindel, Kenneth Fife, Sheena Sutherland, Jacqueline Benedetti, Michael W. Adler Md

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

To determine whether intravenous acyclovir treatment for a first episode of genital herpes could prevent or reduce subsequent recurrences, we combined and analyzed the results of two in­dependently conducted, randomized, double-blind, placebo-con­trolled studies. Sixty-one patients were enrolled in the two trials; 30 received the drug, and 31 received placebo. At entry the de­mographic, epidemiologic, and clinical features of acyclovir- and placebo-treated patients from the two centers showed no signif­icant differences. The median time to the first recurrence and the frequency of recurrences showed no significant differences when acyclovir and placebo recipients infected with either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) were compared. However, irrespective of treatment, the median time to the first recurrence was significantly longer (293 days vs. 69 days; P <.02) and the frequency of recurrence significantly less (0.11 recurrences per month vs. 0.43 recurrences per month; P <.01) among patients with HSV-1 infection as compared with those who had HSV-2. It is concluded that in patients with first-attack genital herpes, the type of HSV is the most important determinant of subsequent recurrences and that intravenous acyclovir has little effect on subsequent recurrences.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalSexually Transmitted Diseases
Volume12
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Herpes Genitalis
Acyclovir
Recurrence
Placebos
Human Herpesvirus 2
Therapeutics
Human Herpesvirus 1
Virus Diseases
Demography

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases
  • Microbiology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Corey, L., Mindel, A., Fife, K., Sutherland, S., Benedetti, J., & Adler Md, M. W. (1985). Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sexually Transmitted Diseases, 12(4), 215-218.

Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. / Corey, Lawrence; Mindel, Adrian; Fife, Kenneth; Sutherland, Sheena; Benedetti, Jacqueline; Adler Md, Michael W.

In: Sexually Transmitted Diseases, Vol. 12, No. 4, 1985, p. 215-218.

Research output: Contribution to journalArticle

Corey, L, Mindel, A, Fife, K, Sutherland, S, Benedetti, J & Adler Md, MW 1985, 'Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir', Sexually Transmitted Diseases, vol. 12, no. 4, pp. 215-218.
Corey, Lawrence ; Mindel, Adrian ; Fife, Kenneth ; Sutherland, Sheena ; Benedetti, Jacqueline ; Adler Md, Michael W. / Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. In: Sexually Transmitted Diseases. 1985 ; Vol. 12, No. 4. pp. 215-218.
@article{891be66842914094988b1f7fa5089921,
title = "Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir",
abstract = "To determine whether intravenous acyclovir treatment for a first episode of genital herpes could prevent or reduce subsequent recurrences, we combined and analyzed the results of two in­dependently conducted, randomized, double-blind, placebo-con­trolled studies. Sixty-one patients were enrolled in the two trials; 30 received the drug, and 31 received placebo. At entry the de­mographic, epidemiologic, and clinical features of acyclovir- and placebo-treated patients from the two centers showed no signif­icant differences. The median time to the first recurrence and the frequency of recurrences showed no significant differences when acyclovir and placebo recipients infected with either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) were compared. However, irrespective of treatment, the median time to the first recurrence was significantly longer (293 days vs. 69 days; P <.02) and the frequency of recurrence significantly less (0.11 recurrences per month vs. 0.43 recurrences per month; P <.01) among patients with HSV-1 infection as compared with those who had HSV-2. It is concluded that in patients with first-attack genital herpes, the type of HSV is the most important determinant of subsequent recurrences and that intravenous acyclovir has little effect on subsequent recurrences.",
author = "Lawrence Corey and Adrian Mindel and Kenneth Fife and Sheena Sutherland and Jacqueline Benedetti and {Adler Md}, {Michael W.}",
year = "1985",
language = "English (US)",
volume = "12",
pages = "215--218",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir

AU - Corey, Lawrence

AU - Mindel, Adrian

AU - Fife, Kenneth

AU - Sutherland, Sheena

AU - Benedetti, Jacqueline

AU - Adler Md, Michael W.

PY - 1985

Y1 - 1985

N2 - To determine whether intravenous acyclovir treatment for a first episode of genital herpes could prevent or reduce subsequent recurrences, we combined and analyzed the results of two in­dependently conducted, randomized, double-blind, placebo-con­trolled studies. Sixty-one patients were enrolled in the two trials; 30 received the drug, and 31 received placebo. At entry the de­mographic, epidemiologic, and clinical features of acyclovir- and placebo-treated patients from the two centers showed no signif­icant differences. The median time to the first recurrence and the frequency of recurrences showed no significant differences when acyclovir and placebo recipients infected with either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) were compared. However, irrespective of treatment, the median time to the first recurrence was significantly longer (293 days vs. 69 days; P <.02) and the frequency of recurrence significantly less (0.11 recurrences per month vs. 0.43 recurrences per month; P <.01) among patients with HSV-1 infection as compared with those who had HSV-2. It is concluded that in patients with first-attack genital herpes, the type of HSV is the most important determinant of subsequent recurrences and that intravenous acyclovir has little effect on subsequent recurrences.

AB - To determine whether intravenous acyclovir treatment for a first episode of genital herpes could prevent or reduce subsequent recurrences, we combined and analyzed the results of two in­dependently conducted, randomized, double-blind, placebo-con­trolled studies. Sixty-one patients were enrolled in the two trials; 30 received the drug, and 31 received placebo. At entry the de­mographic, epidemiologic, and clinical features of acyclovir- and placebo-treated patients from the two centers showed no signif­icant differences. The median time to the first recurrence and the frequency of recurrences showed no significant differences when acyclovir and placebo recipients infected with either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) were compared. However, irrespective of treatment, the median time to the first recurrence was significantly longer (293 days vs. 69 days; P <.02) and the frequency of recurrence significantly less (0.11 recurrences per month vs. 0.43 recurrences per month; P <.01) among patients with HSV-1 infection as compared with those who had HSV-2. It is concluded that in patients with first-attack genital herpes, the type of HSV is the most important determinant of subsequent recurrences and that intravenous acyclovir has little effect on subsequent recurrences.

UR - http://www.scopus.com/inward/record.url?scp=0022410221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022410221&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 215

EP - 218

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 4

ER -